Total Payments
$111,443
2024 Payments
$1,700
Companies
14
Transactions
64
Medicare Patients
760
Medicare Billing
$59,160
Payment Breakdown by Category
Research$106,111 (95.2%)
Travel$3,990 (3.6%)
Food & Beverage$1,322 (1.2%)
Education$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $106,111 | 24 | 95.2% |
| Travel and Lodging | $3,990 | 9 | 3.6% |
| Food and Beverage | $1,322 | 30 | 1.2% |
| Education | $20.00 | 1 | 0.0% |
Payments by Type
Research
$106,111
24 transactions
General
$5,332
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Hill Dermaceuticals, Inc. | $63,979 | 1 | $0 (2021) |
| PFIZER INC. | $38,123 | 8 | $0 (2023) |
| ModernaTX, Inc. | $3,048 | 6 | $0 (2023) |
| Lexicon Pharmaceuticals, Inc. | $1,680 | 3 | $0 (2024) |
| Eli Lilly and Company | $1,569 | 2 | $0 (2023) |
| Janssen Research & Development, LLC | $1,309 | 10 | $0 (2018) |
| Shionogi Inc | $620.71 | 6 | $0 (2017) |
| SANOFI US SERVICES INC. | $608.05 | 9 | $0 (2018) |
| Dr.Reddy's Laboratories,Inc. | $151.79 | 1 | $0 (2017) |
| Genentech USA, Inc. | $135.00 | 9 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,700 | 4 | Lexicon Pharmaceuticals, Inc. ($1,680) |
| 2023 | $41,707 | 15 | PFIZER INC. ($38,123) |
| 2022 | $1,034 | 1 | Eli Lilly and Company ($1,034) |
| 2021 | $64,112 | 4 | Hill Dermaceuticals, Inc. ($63,979) |
| 2020 | $63.76 | 4 | Genentech USA, Inc. ($63.76) |
| 2019 | $80.52 | 6 | Genentech USA, Inc. ($42.99) |
| 2018 | $1,955 | 22 | Janssen Research & Development, LLC ($1,309) |
| 2017 | $791.17 | 8 | Shionogi Inc ($620.71) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/25/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,171.15 | Research |
| Study: LX9211 | ||||||
| 04/25/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $266.45 | Research |
| Study: LX9211 | ||||||
| 04/25/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $242.06 | Research |
| Study: LX9211 | ||||||
| 02/06/2024 | CSL Behring | Kcentra (Biological) | Education | In-kind items and services | $20.00 | General |
| Category: Trauma (Emergency, Injury, Surgery) | ||||||
| 12/14/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $7,839.71 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $54.43 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $4,689.61 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 09/17/2023 | Eli Lilly and Company | — | — | In-kind items and services | $535.01 | Research |
| Study: A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | ||||||
| 08/30/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $12,715.23 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 07/03/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $1,269.39 | General |
| 07/03/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $803.04 | General |
| 07/03/2023 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $325.00 | General |
| 07/03/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $297.72 | General |
| 07/03/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $150.00 | General |
| 05/25/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $12,194.49 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 05/25/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $400.00 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 05/25/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $130.00 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 05/25/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $100.00 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 01/19/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $202.96 | General |
| 04/05/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,034.00 | Research |
| Study: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | ||||||
| 12/01/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Virology & Specialty Care | ||||||
| 03/03/2021 | ORGANOGENESIS INC. | Puraply Antimicrobial (Medical Supply) | Food and Beverage | Cash or cash equivalent | $105.21 | General |
| Category: Wound Care | ||||||
| 02/18/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: Virology & Specialty Care | ||||||
| 01/06/2021 | Hill Dermaceuticals, Inc. | — | — | Cash or cash equivalent | $63,978.80 | Research |
| Study: Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis) • Category: Otic | ||||||
| 12/24/2020 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: Virology & Specialty Care | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis) | Hill Dermaceuticals, Inc. | $63,979 | 1 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $38,123 | 8 |
| LX9211 | Lexicon Pharmaceuticals, Inc. | $1,680 | 3 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $1,034 | 1 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua?100/33 Versus Lantus? in Ethnically/Racially Di | SANOFI US SERVICES INC. | $608.05 | 9 |
| A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $535.01 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura Oral Celecoxib | Dr.Reddy's Laboratories,Inc. | $151.79 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 8 | 273 | 298 | $135,373 | $19,840 |
| 2021 | 7 | 211 | 222 | $30,105 | $18,297 |
| 2020 | 8 | 276 | 290 | $40,892 | $21,023 |
Total Patients
760
Total Services
810
Medicare Billing
$59,160
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 83 | 87 | $15,660 | $8,215 | 52.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 37 | 37 | $10,212 | $5,115 | 50.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 35 | 37 | $4,567 | $2,402 | 52.6% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 47 | 47 | $2,350 | $1,925 | 81.9% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 28 | 29 | $100,744 | $1,471 | 1.5% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 18 | 36 | $1,260 | $591.42 | 46.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 11 | $440.00 | $89.30 | 20.3% |
| 81003 | Automated urinalysis test | Office | 2022 | 14 | 14 | $140.00 | $31.25 | 22.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 66 | 71 | $12,780 | $7,574 | 59.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 37 | 37 | $10,212 | $5,407 | 52.9% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 39 | 41 | $2,255 | $2,104 | 93.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 19 | $2,318 | $1,422 | 61.3% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 18 | 19 | $950.00 | $859.37 | 90.5% |
| 87811 | Sars-cov-2 covid19 w/optic | Office | 2021 | 19 | 19 | $950.00 | $786.22 | 82.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 14 | 16 | $640.00 | $144.56 | 22.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 97 | 104 | $18,685 | $8,545 | 45.7% |
| 87635 | Sars-cov-2 covid-19 amp prb | Office | 2020 | 64 | 69 | $3,795 | $3,540 | 93.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 25 | 25 | $6,900 | $3,119 | 45.2% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 25 | 25 | $4,550 | $2,406 | 52.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 27 | 28 | $3,416 | $1,839 | 53.8% |
| 87502 | Detection test for multiple types influenza virus | Office | 2020 | 14 | 14 | $2,436 | $1,322 | 54.3% |
| 71046 | X-ray of chest, 2 views | Office | 2020 | 11 | 11 | $550.00 | $161.38 | 29.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 13 | 14 | $560.00 | $89.95 | 16.1% |
About Dr. Patrick Dennis, MD
Dr. Patrick Dennis, MD is a Emergency Medical Services healthcare provider based in New Orleans, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1245426774.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Dennis, MD has received a total of $111,443 in payments from pharmaceutical and medical device companies, with $1,700 received in 2024. These payments were reported across 64 transactions from 14 companies. The most common payment nature is "" ($106,111).
As a Medicare-enrolled provider, Dennis has provided services to 760 Medicare beneficiaries, totaling 810 services with total Medicare billing of $59,160. Data is available for 3 years (2020–2022), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medical Services
- Other Specialties Emergency Medical Services
- Location New Orleans, LA
- Active Since 09/19/2007
- Last Updated 01/02/2013
- Taxonomy Code 207PE0004X
- Entity Type Individual
- NPI Number 1245426774
Products in Payments
- ZAVZPRET (Drug) $38,123
- Tremfya (Drug) $1,309
- SOLIQUA (Drug) $608.05
- Xofluza (Drug) $135.00
- Puraply Antimicrobial (Medical Supply) $105.21
- SIVEXTRO (Drug) $51.83
- Karbinal ER (Drug) $42.51
- Kcentra (Biological) $20.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.